Lenacapavir works against the HIV-1 virus by inhibiting viral replication: it interferes with a number of essential steps of the viral lifecycle, including ...

SUNLENCA® Was Granted FDA Breakthrough Therapy Designation and Has a Novel MOA1,2. First–in–class capsid inhibitor that targets HIV–1 at multiple stages ...

The mechanism of action of lenacapavir is as a HIV Capsid Inhibitor, and Cytochrome P450 3A Inhibitor, and P-Glycoprotein Inhibitor, and Breast Cancer ...

LEN is a novel, first-in-class, HIV-1 capsid inhibitor with a multistage mechanism of action and a desirable in vitro profile.

14 июн. 2023 г. · Lenacapavir (Sunlenca®) is a long-acting capsid inhibitor of human immunodeficiency virus type 1 (HIV-1) being developed by Gilead Sciences Inc.

Lenacapavir, sold under the brand name Sunlenca, is an antiretroviral medication used to treat HIV/AIDS. It is taken by mouth or by subcutaneous injection.

Mechanism of Action ... Capsid inhibitor. Lenacapavir is a long-acting, potent inhibitor of the HIV capsid protein with in vitro activity against viral strains ...

26 янв. 2023 г. · MOA: Lenacapavir, a capsid inhibitor, works by blocking the HIV-1 virus' protein shell (the capsid), thereby interfering with multiple essential ...

14 янв. 2022 г. · In clinical studies, lenacapavir has demonstrated successful antiviral activity and adequate pharmacokinetic exposure for up to 6 months after ...

First-in-Class MOA. Efficacy & Resistance. Study ... Maintenance: 927 mg by subcutaneous injection every 26 weeks +/- 2 weeks from date of last injection.